

Belen Arranz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9061464/publications.pdf>

Version: 2024-02-01

38
papers

1,454
citations

411340
20
h-index

371746
37
g-index

41
all docs

41
docs citations

41
times ranked

2041
citing authors

#	ARTICLE	IF	CITATIONS
1	Affective temperaments and sexual functioning in euthymic patients with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2022, 146, 201-209.	1.5	0
2	Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein levels and metabolic status in patients with a bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 464-474.	1.3	4
3	Machine Learning to Understand the Immune-Inflammatory Pathways in Fibromyalgia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4231.	1.8	24
4	Classification of patients with bipolar disorder using k-means clustering. <i>PLoS ONE</i> , 2019, 14, e0210314.	1.1	36
5	Are plasma 25-hydroxyvitamin D and retinol levels and one-carbon metabolism related to metabolic syndrome in patients with a severe mental disorder?. <i>Psychiatry Research</i> , 2019, 273, 22-29.	1.7	2
6	Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review. <i>European Neuropsychopharmacology</i> , 2018, 28, 227-242.	0.3	24
7	Sleep disturbances, functioning, and quality of life in euthymic patients with bipolar disorder. <i>Psychiatry Research</i> , 2018, 269, 501-507.	1.7	23
8	Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial. <i>European Neuropsychopharmacology</i> , 2017, 27, 959-969.	0.3	17
9	How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 422-428.	0.7	24
10	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. <i>Journal of Dual Diagnosis</i> , 2015, 11, 153-160.	0.7	19
11	Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 485-490.	1.0	19
12	The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1421-1425.	1.0	24
13	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. <i>Psychiatry Research</i> , 2012, 200, 693-701.	1.7	29
14	Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. <i>Schizophrenia Research</i> , 2011, 129, 169-171.	1.1	13
15	Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study. <i>European Neuropsychopharmacology</i> , 2011, 21, 861-866.	0.3	17
16	Predictors of schizophrenia in patients with a first episode of psychosis. <i>Psychiatry Research</i> , 2010, 175, 11-14.	1.7	12
17	Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. <i>European Psychiatry</i> , 2008, 23, 396-402.	0.1	95
18	Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders. <i>European Addiction Research</i> , 2007, 13, 230-243.	1.3	35

#	ARTICLE	IF	CITATIONS
19	Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients. <i>Psychiatry Research</i> , 2007, 153, 103-109.	1.7	18
20	The functioning of the Behavioral Activation and Inhibition Systems in bipolar I euthymic patients and its influence in subsequent episodes over an eighteen-month period. <i>Personality and Individual Differences</i> , 2007, 42, 1323-1331.	1.6	59
21	Effect of 5-HT _{1A} Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients. <i>American Journal of Psychiatry</i> , 2006, 163, 1826-1829.	4.0	100
22	Mirtazapine: only for depression?. <i>Acta Neuropsychiatrica</i> , 2006, 18, 130-143.	1.0	12
23	Depression in Schizophrenia, Can it be Treated? A Review of the Evidence. <i>Current Psychiatry Reviews</i> , 2006, 2, 371-379.	0.9	2
24	Polymorphisms of the 5-HT _{2C} receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 195-200.	0.7	237
25	Altered 5-HT _{2A} and 5-HT ₄ Postsynaptic Receptors and Their Intracellular Signalling Systems IP ₃ and cAMP in Brains from Depressed Violent Suicide Victims. <i>Neuropsychobiology</i> , 2004, 49, 189-195.	0.9	71
26	Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 349-356.	1.1	81
27	Insulin Resistance and Increased Leptin Concentrations in Noncompliant Schizophrenia Patients but Not in Antipsychotic-Naive First-Episode Schizophrenia Patients. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1335-1342.	1.1	141
28	Uso combinado de marcadores serotoninérgicos de las plaquetas y escalas psicopatológicas como detección selectiva diagnóstica de un trastorno psicótico frente a uno depresivo. <i>European Psychiatry (Ed Española)</i> , 2004, 11, 58-60.	0.0	0
29	Combined use of platelet serotonergic markers and psychopathological scales as diagnostic screening of a psychotic versus a depressive disorder. <i>European Psychiatry</i> , 2003, 18, 369-371.	0.1	2
30	Altered platelet serotonin 5-HT _{2A} receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients. <i>Psychiatry Research</i> , 2003, 118, 165-174.	1.7	26
31	Different distributions of the 5-HT reuptake complex and the postsynaptic 5-HT _{2A} receptors in Brodmann areas and brain hemispheres. <i>Psychiatry Research</i> , 2002, 111, 105-115.	1.7	11
32	Depression improvement with calcium heparin. <i>General Hospital Psychiatry</i> , 2002, 24, 450-451.	1.2	4
33	Altered 5-HT _{2A} binding sites and second messenger inositol trisphosphate (IP ₃) levels in hippocampus but not in frontal cortex from depressed suicide victims. <i>Psychiatry Research - Neuroimaging</i> , 2000, 99, 173-181.	0.9	73
34	Different regional distribution of the 5-HT reuptake complex, the 5-HT _{2A} receptors and their second messenger IP ₃ in human brain. <i>Neuroscience Research Communications</i> , 1999, 24, 107-115.	0.2	3
35	Variations in [3H]imipramine and 5-HT _{2A} but not [3H]paroxetine binding sites in suicide brains. <i>Psychiatry Research - Neuroimaging</i> , 1998, 82, 161-170.	0.9	29
36	Monitoring Patterns of Substance Use in Drug-Dependent Patients. <i>Journal of Substance Abuse Treatment</i> , 1998, 15, 425-430.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. <i>Biological Psychiatry</i> , 1997, 41, 1000-1009.	0.7	42
38	Brain 5-HT1A, 5-HT1D, and 5-HT2 Receptors in suicide victims. <i>Biological Psychiatry</i> , 1994, 35, 457-463.	0.7	117